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Rate Ratio (IRR) - 1.28, 95% CI:1.09 -1.51) higher rate for number of visits to the office
basedphysicianswhencompared tomales. Blackshad31% (IRR-0.69, 95%CI:0.53-0.89)
lower rate of ambulatory care utilization when compared toWhites. Publicly insured
individuals had 66% (IRR-1.66, 95%CI:1.26-2.18) higher rate of ambulatory care utiliza-
tionwhereas uninsured individuals have 37% (IRR-0.63, 95%CI:0.40-0.99) lower rate of
ambulatory care utilization than the ADHD patients with private health insurance.
CONCLUSIONS: Gender, and racial disparities exist in ambulatory care utilization
among ADHD patients. Providing some kind of health insurance coveragemight help
in reducing thesedisparities andoptimizingambulatory careutilizationamongADHD
patients.
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OBJECTIVES: ADHD is a major concern since it is one of the most commonmental
disorders affecting children and adolescents. The prevalence of ADHD has been
reported to be increasing in the past decade. We assessed the trends in prevalence
of ADHD drug use in the Netherlands from 2000 until 2010. METHODS: From the
PHARMO database, including amongst others, drug dispensing records of approx-
imately 3.2 million inhabitants in The Netherlands, we selected patients with at
least one dispensing of ADHDmedication includingmethylphenidate, dexamphet-
amine and atomoxetine, between 2000 and 2010. For each calendar year, patients
were counted as prevalent ADHDdrug users if they received a dispensing for ADHD
treatment in the respective calendar year. The number of ADHD drug users in
PHARMOwas divided by the number of residents in PHARMO andmultiplied by the
number of inhabitants in the Netherlands, standardized for age and gender. Re-
sults were stratified by age groups and gender. RESULTS: The prevalence of ADHD
drug treatment among males was higher than among femals. From 2000 to 2010,
the prevalence among children (0-12 years) has increased 2.6-fold in males (from
158 to 410 per 10,000) and 4.5-fold in females (from 27 - 119 per 10,000). The prev-
alence among adolescents (13-18 years) has increased 4.0-fold in males (170 - 675
per 10,000) and 7.4-fold in females (27 - 200 per 10,000). The prevalence among
adults (19 years) has increased 8.2-fold in males (from 8 - 63 per 10,000) and
10.1-fold in females (from 4 - 43 per 10,000). CONCLUSIONS: This study provides a
comprehensive overview of trends in prevalence of ADHD drug treatment in The
Netherlands. Both in males and females, a continuous increase in prevalence was
observed.
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OBJECTIVES: ADHD has become a much debated topic in the last few years. More
attention and awareness for ADHD has led to an increase in incidence. Especially
awareness for the subtype of ADHD where patients, mostly females, demonstrate
predominantly inattentive symptoms, has increased. We determined the male/
female incidence ratio of ADHD drug treatment in the Netherlands from 2000 until
2010. METHODS: From the PHARMO database, including amongst others, drug
dispensing records of approximately 3.2million inhabitants in theNetherlands, we
selected patients with a first dispensing of ADHD medication including methyl-
phenidate, atomoxetine and dexamphetamine in the period 2000-2010. For each
calendar year, the male/female incidence ratio of ADHD drug use was determined
by dividing the incidence among males by the incidence among females. Results
were stratified by age groups. RESULTS:Overall, themale/female incidence ratio of
ADHD drug treatment decreased from 3.4:1 in 2000 to 1.6:1 in 2010, meaning a
growing proportion of female patients. The largest decrease in the male/female
ratio was observed among adolescents (13-18 years: from 4.5:1 in 2000 to 1.6:1 in
2010), followed by 9-12 year-olds (from5.5:1 in 2000 - 2.7:1 in 2010) and 0-8 year-olds
(from 6.2:1 in 2000 - 3.5:1 in 2010). Among adults and seniors this ratio fluctuated
from 0.9:1 to 2.1:1. Although the incidence among females has increasedmore over
the years, the incidence among males remained higher throughout the study
period. CONCLUSIONS: This study shows that the proportion of female patients
starting ADHD drug treatment is increasing. This in line with the increased aware-
ness of ADHD among females.
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OBJECTIVES: To examine the association between obesity and depression/anxiety
and related expenditures in children and adolescents.METHODS: Data from Med-
ical Expenditure Panel Survey (MEPS) longitudinal panels 9, 10, 11 and 12 were
combined to analyze the risk of depression/anxiety in a cohort of children and
adolescents (aged 6-17 years). Incident depression/anxiety was identified during
one year follow-up using Clinical Classification Codes (CCCODEX) for depression
(657) and anxiety (651) or by Multum Lexicon Therapeutic Classification Codes for
anti-anxiety (067) or antidepressant (249) drugs. Body Mass Index (BMI)-for-age 
85th-percentile of the 2000 sex-specific Center for Disease Control (CDC) BMI-for-
age growth charts, was considered obese/overweight. Due to possibility of reverse
causality, instrument variable model with the BMI of mother and its square as
exogenous measures for overweight status was evaluated. Two stage analyses,
however, revealed that overweight status was not an endogenous variable. Conse-
quently, association between obesity and depression/anxiety was evaluated using
multivariate logistic regression. The risk of increased depression/anxiety expendi-
tures was examined using a two part expenditure model was used. RESULTS: An
estimated 3.67 million (95% Confidence Interval (CI): 3.47-3.87) were obese/over-
weight in national weighted sample 10.34 million children and adolescents. The
incidence depression/anxiety among obese/overweight and non-overwight chil-
dren was 0.95and 1.75%, respectively. Multivariable analysis of a nationally repre-
sentative sample of children and adolescents indicated no significant association
between obese/overweight status and development of depression/anxiety [Ad-
justed Odds Ratio (AOR):0.65; 95% Confidence Interval (CI): 0.65-1.37]. In addition,
there was no increased f risk of depression/anxiety related expenditure (AOR: 1.39;
95% CI: 0.67-2.90), nor the risk of an increased amount of expenditure (t-statistic:
-0.41; P-value: 0.19) due to obesity/overweight. CONCLUSIONS: Obese/overweight
children and adolescents in this nationally representative community sample did
not have an increased likelihood of depression/anxiety. Thus, obese/overweight
children and adolescents may not always suffer from psychological distress.
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OBJECTIVES: Long-acting therapy (LAT) formulations of atypical antipsychotics
(AAPs) remove the need for dailymedication in the treatment of schizophrenia and
may improve outcomes. Little is known about LAT AAP use during inpatient ad-
missions. This study identifies factors associated with LAT AAP use among inpa-
tients with schizophrenia. METHODS: A retrospective analysis (2007-2010) of the
Health Facts® database (Cerner Corp., Kansas City, MO) identified adult patients
with a primary discharge diagnosis of schizophrenia and1 order for AAP. Factors
examined included demographic, clinical, and treatment setting characteristics. A
bootstrapping algorithmwithmultilevel (hierarchical) logistic regressionwas used
to identify factors most strongly associated with LAT AAP exposure. RESULTS: A
total of 3230 admissions met inclusion criteria; 217 had LAT AAP exposure. Before
regression adjustment, key factors with a significantly greater likelihood of LAT
AAP use included receiving oral risperidone (85.3% vs 35.0%, p0.001) and being
treated in a facility with500 beds (48.9% vs 31.5%, p0.001). Negative associations
included Caucasian race (47.9% vs 55.4%, p0.033), receiving most other oral AAPs
(varies by agent), and being treated in a facility with 500 beds (varies by categor-
ical size). Factors not significantly associatedwith LATAAP use included age, use of
first-generation antipsychotics, urgent admission, and treatment in a teaching fa-
cility. The regression model had good discrimination (c-statistic  0.85); factors
associated with a greater likelihood of LAT AAP exposure were male gender
(OR1.58, p0.005), diagnosis of chronic respiratory conditions (OR1.64, p0.014),
affective disorders not meeting criteria for full mood disorder (OR1.95, p0.004),
and oral risperidone (OR11.05, p0.001). Patients using olanzapine (OR0.64,
p0.057) or antidepressants (OR0.75, p0.065) trended toward not receiving LAT
AAP. CONCLUSIONS: LAT AAP use in the inpatient setting was related to gender,
certain chronic conditions, specific AAP and antidepressant use, and facility size.
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OBJECTIVES: Several stimulant and non-stimulant medications are indicated and
used alone or in combination to treat attention deficit hyperactivity disorder
(ADHD). Little is known about polypharmacy prevalence and predictors in this
population. The objective of this analysis was to describe ADHD medication utili-
zation patterns focusing on combination versus monotherapy.METHODS: Health
insurance claims from Thomson Reuters MarketScan Commercial Database were ana-
lyzed for patients with an ADHD diagnosis (ICD-9 314.0x). Patients included were
age6 as of January 2010, continuously enrolled July 2009 through December 2010,
and with a 2010 ADHD medication claim. Medication utilization was measured at
the patient-month level during 2010. Generalized-estimating equations were used
to account for within-patient correlation between months. Demographic and clin-
ical predictors were explored with atomoxetine (ATX), long-acting stimulants
(LAS), and alpha-2-adrenergic agents (A2A). RESULTS: ADHD patients (n268,172)
were primarily age 6-17 years old (57.9%) andmale (61.2%). ADHDwith hyperactiv-
itywas present in 14.2%.Of all treatment-months, 10.3%were combination therapy
(more than one ADHD medication class in same month). Short-acting stimulants
and A2A agents had the highest combination use (45.3%, 54.0% respectively). ATX,
LAS, intermediate-acting stimulants, and prodrug stimulants had the lowest per-
centage combination use (17.9%, 13.6%, 21.8%, 9.9% respectively), ATX combination
therapy was less in older patients (age 18 adjusted odds ratios [AOR] between
0.332-0.829), LAS agents were more frequently used (ages 18-44 AOR 1.079-1.457)
and A2A had no association (age 25 AOR 0.699-1.083). Females were less likely to
use combination therapy. Hyperactivity was associated with combination therapy
in all three models. Tics/Tourettes was associated with combination therapy for
ATX and LAS. CONCLUSIONS: Combination therapy rates differed by medication
class, as did the demographic and clinical characteristics that significantly pre-
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